BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 10622624)

  • 1. PCR follow-up examination after treatment of canine leishmaniosis (CaL).
    Steuber S; Moritz A; Schirrmann I; Greiner M
    Tokai J Exp Clin Med; 1998 Dec; 23(6):285-92. PubMed ID: 10622624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical follow-up examination after treatment of canine leishmaniasis.
    Moritz A; Steuber S; Greiner M
    Tokai J Exp Clin Med; 1998 Dec; 23(6):279-83. PubMed ID: 10622623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different tissue sampling for PCR-based diagnosis and follow-up of canine visceral leishmaniosis.
    Manna L; Vitale F; Reale S; Caracappa S; Pavone LM; Morte RD; Cringoli G; Staiano N; Gravino AE
    Vet Parasitol; 2004 Nov; 125(3-4):251-62. PubMed ID: 15482882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol.
    Manna L; Reale S; Vitale F; Picillo E; Pavone LM; Gravino AE
    Vet J; 2008 Aug; 177(2):279-82. PubMed ID: 17553711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
    Miró G; Oliva G; Cruz I; Cañavate C; Mortarino M; Vischer C; Bianciardi P
    Vet Dermatol; 2009 Oct; 20(5-6):397-404. PubMed ID: 20178476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
    Torres M; Bardagí M; Roura X; Zanna G; Ravera I; Ferrer L
    Vet J; 2011 Jun; 188(3):346-51. PubMed ID: 20594876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate.
    Pasa S; Toz SO; Voyvoda H; Ozbel Y
    Vet Parasitol; 2005 Mar; 128(3-4):243-9. PubMed ID: 15740861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
    Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
    Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of prednisone on haemostasis in leishmaniotic dogs treated with meglumine antimoniate and allopurinol.
    Cortese L; Pelagalli A; Piantedosi D; Mastellone V; Di Loria A; Lombardi P; Ciaramella P; Avallone L
    Vet J; 2008 Sep; 177(3):405-10. PubMed ID: 17629526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
    Manna L; Vitale F; Reale S; Picillo E; Neglia G; Vescio F; Gravino AE
    Vet J; 2009 Dec; 182(3):441-5. PubMed ID: 18818112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
    Miranda S; Martorell S; Costa M; Ferrer L; Ramis A
    Vet Parasitol; 2007 Mar; 144(3-4):251-60. PubMed ID: 17110042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid clearance of circulating Leishmania kinetoplast DNA after treatment of visceral leishmaniasis.
    Disch J; Oliveira MC; Orsini M; Rabello A
    Acta Trop; 2004; 92(3):279-83. PubMed ID: 15533299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of PCR-RFLP to identify Leishmania species in naturally-infected dogs.
    de Andrade HM; Reis AB; dos Santos SL; Volpini AC; Marques MJ; Romanha AJ
    Vet Parasitol; 2006 Sep; 140(3-4):231-8. PubMed ID: 16682124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCR identification of Leishmania in diagnosis and control of canine Leishmaniasis.
    Gomes AH; Ferreira IM; Lima ML; Cunha EA; Garcia AS; Araújo MF; Pereira-Chioccola VL
    Vet Parasitol; 2007 Mar; 144(3-4):234-41. PubMed ID: 17196339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S; Marr JJ
    N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short report: Contribution of quantitative real-time polymerase chain reaction to follow-up of visceral leishmaniasis patients treated with meglumine antimoniate.
    Aoun K; Chouihi E; Amri F; Ben Alaya N; Raies A; Mary C; Bouratbine A
    Am J Trop Med Hyg; 2009 Dec; 81(6):1004-6. PubMed ID: 19996428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periodic administration of allopurinol is not effective for the prevention of canine leishmaniosis (Leishmania infantum) in the endemic areas.
    Saridomichelakis MN; Mylonakis ME; Leontides LS; Billinis C; Koutinas AF; Galatos AD; Gouletsou P; Diakou A; Kontos VI
    Vet Parasitol; 2005 Jun; 130(3-4):199-205. PubMed ID: 15905034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission.
    João A; Pereira MA; Cortes S; Santos-Gomes GM
    J Vet Med A Physiol Pathol Clin Med; 2006 Dec; 53(10):540-5. PubMed ID: 17105576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate.
    Saridomichelakis MN; Xenoulis PG; Chatzis MK; Kasabalis D; Steiner JM; Suchodolski JS; Petanides T
    Vet Parasitol; 2013 Oct; 197(1-2):22-8. PubMed ID: 23685064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate.
    Ikeda-Garcia FA; Lopes RS; Ciarlini PC; Marques FJ; Lima VM; Perri SH; Feitosa MM
    Res Vet Sci; 2007 Aug; 83(1):105-8. PubMed ID: 17150234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.